<![CDATA[Neoadjuvant Nivolumab/Ipilimumab Shows Superior EFS in Resectable Melanoma]]> Cancer Network | November 5, 2025 Topics: skin-cancer, immunotherapy Read the full article at Cancer Network Back to Latest Cancer Research | Our Sources | Subscribe to Newsletter